The Susan G. Komen Foundation and the Ovarian Cancer National Alliance have both urged the FDA not to rule against Avastin. These groups rightly want to leave treatment decisions in the hands of women and their doctors.
When the FDA makes its Avastin decision this month, I hope it rules in favor of empowering patients and continues to give thousands of women access to the same drug that gave my mother hope and life.
Holly Pitt Young is a Washington public relations executive.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
By John Solomon
How the government's punishing of the exposure of official wrongdoing can linger for years